

Paolo Gionchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145381/publications.pdf>

Version: 2024-02-01

206
papers

21,232
citations

15504

65
h-index

9861

141
g-index

210
all docs

210
docs citations

210
times ranked

13783
citing authors

#	ARTICLE	IF	CITATIONS
1	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	1.3	1,547
2	Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. <i>Gastroenterology</i> , 2000, 119, 305-309.	1.3	1,373
3	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 649-670.	1.3	1,324
4	Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. <i>Gastroenterology</i> , 2003, 124, 1202-1209.	1.3	1,048
5	Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. <i>Gut</i> , 2004, 53, 108-114.	12.1	783
6	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	1.3	741
7	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 63-101.	1.3	695
8	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1539-1546.	0.4	659
9	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	1.3	558
10	Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1103-1108.	3.7	485
11	Modulation of human dendritic cell phenotype and function by probiotic bacteria. <i>Gut</i> , 2004, 53, 1602-1609.	12.1	483
12	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	1.3	478
13	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	1.3	422
14	Interaction of probiotic <i>Lactobacillus</i> and <i>Bifidobacterium</i> strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production. <i>International Journal of Food Microbiology</i> , 2008, 125, 286-292.	4.7	344
15	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	4.4	316
16	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	1.3	288
17	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 4-25.	1.3	285
18	Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis. <i>American Journal of Pathology</i> , 1999, 155, 331-336.	3.8	259

#	ARTICLE	IF	CITATIONS
19	A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1485-1493.e2.	4.4	256
20	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
21	Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. <i>FEMS Immunology and Medical Microbiology</i> , 2003, 38, 165-172.	2.7	241
22	Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 713-718.	3.7	214
23	Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. <i>Gut</i> , 2006, 55, 833-841.	12.1	211
24	European evidence-based Consensus on the management of ulcerative colitis: Special situations. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 63-92.	1.3	206
25	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. <i>American Journal of Gastroenterology</i> , 2001, 96, 2691-2699.	0.4	193
26	Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?. <i>Gastroenterology</i> , 1999, 116, 1246-1249.	1.3	188
27	Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 909-917.	3.7	185
28	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	4.4	181
29	High-Dose Probiotics for the Treatment of Active Pouchitis. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 2075-2084.	1.3	179
30	Bacteria as the cause of ulcerative colitis. <i>Gut</i> , 2001, 48, 132-135.	12.1	169
31	Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2012, 142, 473-481.e4.	1.3	165
32	The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 501-512.	3.7	152
33	Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 724-734.	3.7	146
34	Implications of the Westernized Diet in the Onset and Progression of IBD. <i>Nutrients</i> , 2019, 11, 1033.	4.1	142
35	Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1220-1221.	2.3	135
36	Oral budesonide in the treatment of chronic refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1231-1236.	3.7	129

#	ARTICLE	IF	CITATIONS
37	Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 93-97.	1.3	127
38	Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. <i>European Journal of Radiology</i> , 2007, 62, 114-121.	2.6	125
39	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2011, 43, 1-20.	0.9	125
40	Antibiotics and probiotics in treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 3306.	3.3	122
41	Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1109-1116.	3.7	119
42	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 84-92.	0.4	116
43	Variable Response to Probiotics in Two Models of Experimental Colitis in Rats. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 399-406.	1.9	115
44	Probiotics in infective diarrhoea and inflammatory bowel diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 489-493.	2.8	114
45	Clinical guidelines for the management of pouchitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1424-1431.	1.9	111
46	Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. <i>Gut</i> , 1991, 32, 929-931.	12.1	105
47	<i>Lactobacilli, bifidobacteria</i> and <i>E. coli</i> nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. <i>World Journal of Gastroenterology</i> , 2006, 12, 5978.	3.3	104
48	Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 759-764.	3.7	97
49	Local Injection of Infliximab for the Treatment of Perianal Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 768-774.	1.3	96
50	Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1471-1480.	3.7	94
51	Changes in Splanchnic Hemodynamics in Inflammatory Bowel Disease Non-Invasive Assessment by Doppler Ultrasound Flowmetry. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 501-507.	1.5	90
52	Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1890-1897.	2.3	88
53	Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2007, 133, 808-817.	1.3	87
54	New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. <i>Neurogastroenterology and Motility</i> , 2013, 25, 147.	3.0	87

#	ARTICLE	IF	CITATIONS
55	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1180-1186.	1.9	86
56	Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. <i>Clinical and Experimental Immunology</i> , 2003, 132, 473-476.	2.6	84
57	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	5.8	84
58	Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus " A GISC study. <i>European Journal of Human Genetics</i> , 1999, 7, 567-573.	2.8	81
59	Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 251-256.	3.7	79
60	European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw188.	1.3	79
61	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor- α in ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2923-2928.	0.4	74
62	Adalimumab in active ulcerative colitis: A "real-life" observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.9	72
63	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. <i>Digestive Diseases and Sciences</i> , 1992, 37, 29-32.	2.3	70
64	Mucosal concentrations of interleukin- 1β , interleukin-6, interleukin-8, and tumor necrosis factor- α in pelvic ileal pouches. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1525-1531.	2.3	69
65	Antimicrobials in the Management of Inflammatory Bowel Disease. <i>Digestion</i> , 2006, 73, 77-85.	2.3	68
66	Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. <i>Digestive Diseases and Sciences</i> , 1991, 36, 174-178.	2.3	65
67	Brain functional changes in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1769-1777.	1.9	65
68	p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. <i>Lancet, The</i> , 1994, 344, 886-887.	13.7	64
69	Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2589-2594.	2.3	61
70	Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin- 1β , Interleukin-8, and Interferon- γ Gene Expression. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 447-454.	1.9	61
71	Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 291-297.	2.2	59
72	A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 381-388.	3.7	57

#	ARTICLE	IF	CITATIONS
73	Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 125-130.	1.6	55
74	CT-guided percutaneous pelvic abscess drainage in Crohn's disease. <i>Techniques in Coloproctology</i> , 2006, 10, 99-105.	1.8	55
75	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	1.3	53
76	Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. <i>International Journal of Colorectal Disease</i> , 1990, 5, 79-81.	2.2	52
77	Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 361-366.	3.7	52
78	Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 881-887.	3.7	51
79	Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. <i>Digestive and Liver Disease</i> , 2007, 39, 329-337.	0.9	51
80	Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. <i>Journal of Behavioral Medicine</i> , 2013, 36, 477-487.	2.1	51
81	Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy. <i>Dermatology</i> , 2007, 215, 295-300.	2.1	49
82	Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. <i>World Journal of Gastroenterology</i> , 2006, 12, 5987.	3.3	47
83	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.9	47
84	Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. <i>Diseases of the Colon and Rectum</i> , 1986, 29, 108-110.	1.3	45
85	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.9	42
86	Probiotics for the treatment of postoperative complications following intestinal surgery. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 821-831.	2.4	41
87	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.9	39
88	Rifaximin systemic absorption in patients with ulcerative colitis. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 91-93.	1.9	38
89	Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 321-330.	1.9	38
90	Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of x-ray-demonstrated lesions of crohn's disease. <i>Digestive Diseases and Sciences</i> , 1993, 38, 433-437.	2.3	37

#	ARTICLE	IF	CITATIONS
91	Diagnosis and treatment of pouchitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 75-87.	2.4	37
92	Standard Treatment of Ulcerative Colitis. <i>Digestive Diseases</i> , 2003, 21, 157-167.	1.9	37
93	Risk of permanent stoma in extensive Crohn's colitis: the impact of biological drugs. <i>Colorectal Disease</i> , 2013, 15, 1115-1122.	1.4	37
94	Oral beclomethasone dipropionate in chronic refractory pouchitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 649-653.	1.3	37
95	A current overview of corticosteroid use in active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 557-561.	3.0	37
96	Mucosal healing in pediatric Crohn's disease after anti-TNF therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 458-465.	1.6	36
97	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
98	Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1311-1316.	3.7	35
99	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.9	34
100	Adult Attachment and Early Parental Experiences in Patients With Crohn's Disease. <i>Psychosomatics</i> , 2010, 51, 208-215.	2.5	34
101	Systems Biology Approaches for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2104-2114.	1.9	32
102	COVID-19 in IBD: The experience of a single tertiary IBD center. <i>Digestive and Liver Disease</i> , 2021, 53, 271-276.	0.9	32
103	Infliximab in the treatment of Crohn's disease. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 301-308.	2.0	32
104	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. <i>Digestive and Liver Disease</i> , 2004, 36, 121-124.	0.9	31
105	Attachment and quality of life in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2014, 29, 1291-1296.	2.2	31
106	Inflammatory Bowel Diseases and Spondyloarthropathies. <i>Journal of rheumatology Supplement</i> , The, 2015, 93, 21-23.	2.2	31
107	Prediction of relapse in patients with Crohn's disease in remission. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 955-962.	1.6	30
108	VSL#3: An Analysis of Basic and Clinical Contributions in Probiotic Therapeutics. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 499-513.	2.2	30

#	ARTICLE	IF	CITATIONS
109	Local Injection of Adalimumab for Perianal Crohn's Disease: Better Than Infliximab?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1631.	1.9	29
110	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	1.0	29
111	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, A377.	1.3	28
112	Implications of antioxidant enzymes in human gastric neoplasms. <i>International Journal of Molecular Medicine</i> , 2009, 24, 693-700.	4.0	27
113	Parental Bonding and Inflammatory Bowel Disease. <i>Psychosomatics</i> , 2010, 51, 14-21.	2.5	27
114	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
115	Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo controlled trial. <i>Gastroenterology</i> , 2000, 118, A190.	1.3	26
116	Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. <i>Clinical and Experimental Immunology</i> , 2001, 123, 395-401.	2.6	26
117	Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. <i>Journal of Ultrasound</i> , 2017, 20, 273-284.	1.3	26
118	Probiotics and antibiotics in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 331-335.	2.3	25
119	The effect of transient intestinal ischemia on inflammatory parameters. <i>International Journal of Colorectal Disease</i> , 2003, 18, 78-85.	2.2	24
120	Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 273-279.	1.3	24
121	Potential role for the common cystic fibrosis ΔF508 mutation in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 531-536.	1.9	23
122	Sympathetic hyperactivity in patients with ulcerative colitis. <i>Clinical Autonomic Research</i> , 2007, 17, 217-220.	2.5	22
123	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018, 50, 653-660.	0.9	22
124	Usefulness of panoramic 344°-viewing in Crohn's disease capsule endoscopy: a proof of concept pilot study with the novel PillCam, Crohn's system. <i>BMC Gastroenterology</i> , 2020, 20, 97.	2.0	22
125	Parental Bonding and Inflammatory Bowel Disease. <i>Psychosomatics</i> , 2010, 51, 14-21.	2.5	22
126	The role of antibiotics and probiotics in pouchitis. <i>Annals of Gastroenterology</i> , 2012, 25, 100-105.	0.6	22

#	ARTICLE	IF	CITATIONS
127	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.9	22
128	Probiotics and barrier function in colitis. <i>Gut</i> , 2005, 54, 898-900.	12.1	21
129	Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 675-685.	3.3	21
130	Management of Inflammatory Bowel Disease: Does Rifaximin Offer Any Promise?. <i>Chemotherapy</i> , 2005, 51, 96-102.	1.6	20
131	Parvovirus B19 Infection Localized in the Intestinal Mucosa and Associated with Severe Inflammatory Bowel Disease. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1591-1595.	3.9	20
132	Obscure gastrointestinal bleeding: single centre experience of capsule endoscopy. <i>Internal and Emergency Medicine</i> , 2013, 8, 681-687.	2.0	20
133	Absence of change in the gray matter volume of patients with ulcerative colitis in remission: a voxel based morphometry study. <i>BioPsychoSocial Medicine</i> , 2015, 9, 1.	2.1	20
134	Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. <i>Digestive Diseases and Sciences</i> , 1997, 42, 2606-2611.	2.3	19
135	Increased risk of breast cancer in first-degree relatives of Crohn's disease patientsAn IG-IBD study. <i>Digestive and Liver Disease</i> , 2006, 38, 18-23.	0.9	19
136	Clinical course of microscopic colitis in a single-center cohort study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 218-221.	1.3	19
137	The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1175-1181.	3.0	19
138	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	1.8	19
139	CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. <i>International Journal of Colorectal Disease</i> , 2004, 19, 165-170.	2.2	18
140	Eviendep ^Â reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. <i>World Journal of Gastroenterology</i> , 2013, 19, 5671.	3.3	18
141	Recognition of Bactericidal/Permeability-Increasing Protein by Perinuclear Anti-Neutrophil Cytoplasmic Antibody-Positive Sera from Ulcerative Colitis Patients: Prevalence and Clinical Significance. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1284-1288.	1.5	17
142	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	2.9	16
143	5-Aminosalicylic acid suppositories in the management of ulcerative colitis. <i>Diseases of the Colon and Rectum</i> , 1989, 32, 398-399.	1.3	15
144	Probiotics in gastroenterology. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 235-239.	2.3	15

#	ARTICLE	IF	CITATIONS
145	Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis. <i>Journal of Rheumatology</i> , 2017, 44, 1341-1346.	2.0	15
146	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 613-620.	0.9	14
147	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020, 52, 506-515.	0.9	14
148	Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. <i>Digestive Diseases and Sciences</i> , 1994, 39, 550-554.	2.3	13
149	Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 250-255.	3.7	13
150	IBD and spondyloarthritis: joint management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 9-10.	17.8	13
151	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.9	13
152	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	3.7	13
153	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	1.5	12
154	Management of pouch dysfunction or pouchitis with an ileoanal pouch. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 993-1006.	2.4	12
155	Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. <i>World Journal of Gastroenterology</i> , 2010, 16, 30-41.	3.3	12
156	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	3.1	11
157	Pouchitis: Clinical Features, Diagnosis, and Treatment. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3871-3879.	1.8	11
158	Role of conventional therapies in the era of biological treatment in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 1797.	3.3	11
159	Prophylaxis of pouchitis onset with probiotic therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 835.	1.6	10
160	Relapsing ulcerative colitis after spinal cord stimulation: A case of intestinal neurogenic inflammation?. <i>Gastroenterology</i> , 1999, 117, 1256-1257.	1.3	9
161	Probiotic Therapy to Prevent Pouchitis Onset. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1493.	1.3	9
162	Potential role of the cannabinoid receptor CB ₁ in the pathogenesis of erosive and non-erosive gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 603-611.	3.7	9

#	ARTICLE	IF	CITATIONS
163	The role of Budesonide-MMX in active ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2014, 8, 215-222.	3.0	9
164	Transabdominal salvage surgery after pouch failure in a tertiary center: A case-matched study. Digestive and Liver Disease, 2018, 50, 446-451.	0.9	9
165	Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 607-613.	3.0	9
166	Predictors of early recurrence after strictureplasty for Crohn's disease of the small bowel during the years of biologics. Digestive and Liver Disease, 2019, 51, 663-668.	0.9	9
167	Can supplementation of phytoestrogens/insoluble fibers help the management of duodenal polyps in familial adenomatous polyposis?. Carcinogenesis, 2016, 37, 600-606.	2.8	8
168	The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Expert Opinion on Drug Safety, 2018, 17, 963-969.	2.4	8
169	Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease.. Gut, 1993, 34, 1289-1290.	12.1	7
170	Immunoregulatory activity of rifaximin associated with a resistant mutant of Bifidobacterium infantis. International Journal of Antimicrobial Agents, 2009, 33, 387-389.	2.5	7
171	Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn's Disease. Crohn's & Colitis 360, 2020, 2, .	1.1	7
172	Strictureplasty for Crohn's disease of the small bowel in the biologic era: long-term outcomes and risk factors for recurrence. Techniques in Coloproctology, 2020, 24, 711-720.	1.8	7
173	Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. Inflammatory Bowel Diseases, 2023, 29, 76-84.	1.9	6
174	Distinct proteomic profiles characterise non-erosive from erosive reflux disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 982-993.	3.7	5
175	Four cases of carcinoid tumour in Crohn's disease: coincidence or correlation?. International Journal of Colorectal Disease, 2013, 28, 1743-1745.	2.2	5
176	Sequential rescue therapy in steroid-refractory ulcerative colitis. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 521-523.	17.8	5
177	Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease. Pathology, 2014, 46, 439-443.	0.6	4
178	Sporadic small bowel tumors detected by capsule endoscopy in patients with occult gastrointestinal bleeding. Internal and Emergency Medicine, 2015, 10, 781-785.	2.0	4
179	Long term remission after ileorectal anastomosis in Crohn's colitis. Digestive and Liver Disease, 2021, 53, 592-597.	0.9	4
180	Ileal pouchitis-related arthritis. Seminars in Arthritis and Rheumatism, 2002, 32, 204-205.	3.4	4

#	ARTICLE	IF	CITATIONS
181	Macrophage subpopulations and interleukin-1 β tissue levels in pelvic ileal pouches. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 217-222.	1.6	3
182	Medical treatment of ulcerative colitis. <i>Current Opinion in Gastroenterology</i> , 1996, 12, 352-355.	2.3	3
183	MCP-3 in inflammatory bowel disease Reply. <i>Gut</i> , 2000, 47, 155-155.	12.1	2
184	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	2
185	Clinical management of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 1993, 9, 571-581.	2.3	1
186	Efficacy of a symbiotic preparation on functional intestinal disorders (FD) with altered bowel habit: A double-blind controlled study. <i>Gastroenterology</i> , 2001, 120, A750-A751.	1.3	1
187	Role of probiotics in inflammatory bowel disease and intestinal infections. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1277-1283.	5.0	1
188	Corrigendum to "European evidence-based consensus on the management of ulcerative colitis: Special situations" [<i>J Crohn's & Colitis</i> 2 (2008) 63-92]. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 191.	1.3	1
189	Rescue therapy: ciclosporin or infliximab?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 503-505.	3.0	1
190	Probiotics, Prebiotics, and Antibiotics in IBD. , 2017, , 455-469.		1
191	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018, 36, 346-353.	1.9	1
192	Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease. , 2012, , 517-534.		1
193	Pre-ileitis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 964-964.	3.7	0
194	Attualità e controversie nella terapia delle malattie infiammatorie croniche intestinali. <i>Italian Journal of Medicine</i> , 2009, 3, 179-186.	0.3	0
195	Adalimumab in a patient with steroid-dependent Crohn's disease. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 38-39.	0.2	0
196	News and controversy in inflammatory bowel disease treatment. <i>Italian Journal of Medicine</i> , 2013, , 179-186.	0.3	0
197	Clinical management of severe active ulcerative colitis in the TNF- α inhibitors era. <i>Italian Journal of Medicine</i> , 2013, 7, 272.	0.3	0
198	Risks and Benefits of Mucosal Healing With Combined Immunosuppression in Paediatric Crohn's Disease: A Complex Topic That Needs Careful Evaluation. <i>Journal of Crohn's and Colitis</i> , 2016, 11, 220.	1.3	0

#	ARTICLE	IF	CITATIONS
199	Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	0
200	Pouchitis. , 2009, , 195-205.		0
201	Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 4496.	3.3	0
202	Management and treatment of distal ulcerative colitis. <i>Italian Journal of Medicine</i> , 2013, 7, 265.	0.3	0
203	Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?. <i>Updates in Surgery Series</i> , 2019, , 93-104.	0.1	0
204	Author's reply. <i>Annals of Gastroenterology</i> , 2012, 25, 371.	0.6	0
205	New endoscopic capsule vs upper gastrointestinal endoscopy in preoperative work-up of obese candidate for bariatric surgery: Relevance of a pilot study in the COVID-19 era. <i>Endoscopy International Open</i> , 2022, 10, E183-E191.	1.8	0
206	PANENTERIC CAPSULE ENDOSCOPY TO CHARACTERIZE CROHNâ€™S DISEASE PHENOTYPES AND PREDICT CLINICAL OUTCOMES IN CHILDREN AND ADULTS. <i>Gastrointestinal Endoscopy</i> , 2022, 95, AB429.	1.0	0